Prekyba Bristol-Myers Squibb Co - BMY CFD
Pridėti prie mėgstamų- Santrauka
- Istoriniai duomenys
- Įvykiai
- Pajamų ataskaita
- Balansas
- Pinigų srautai
- Nuosavybė
Prekybos sąlygos
| Skirtumas | 0.16 | ||||||||
|
Ilgos pozicijos nakties mokestis
Long position overnight fee
Eiti į platformą | -0.030779% | ||||||||
|
Trumpos pozicijos nakties mokestis
Short position overnight fee
Eiti į platformą | -0.013666% | ||||||||
| Nakties mokesčio laikas | 22:00 (UTC) | ||||||||
| Mažiausias parduodamas kiekis | 1 | ||||||||
| Valiuta | USD | ||||||||
| Marža | 20% | ||||||||
| Akcijų birža | United States of America | ||||||||
| Prekybos mokesčiai | 0% |
*Information provided by Capital.com
Bristol-Myers Squibb Co ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Pagrindiniai statistiniai duomenys
| Ankstesnis uždarymas* | 74.45 |
| Atviras* | 74.34 |
| 1 metų pokytis* | 14.25% |
| Dienos intervalas* | 74.03 - 74.55 |
| 52 savaičių intervalas | 65.00-81.44 |
| Vidutinė apimtis (10 dienų) | 8.52M |
| Vidutinė apimtis (3 mėn.) | 183.36M |
| Rinkos kapitalizacija | 158.46B |
| P/E santykis | 25.25 |
| Neišpirktos akcijos | 2.13B |
| Pajamos | 46.16B |
| EPS | 2.95 |
| Dividendai (pajamingumas %) | 3.05917 |
| Beta | 0.44 |
| Kito pelno data | Apr 27, 2023 |
Visus duomenis pateikė Refinitiv, išskyrus žvaigždute pažymėtus duomenis, kurie yra Capital.com pateikti *duomenys
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Uždarymas | Change | Change (%) | Atidarymas | High | Low |
|---|---|---|---|---|---|---|
| Feb 7, 2023 | 74.43 | 0.36 | 0.49% | 74.07 | 74.61 | 73.90 |
| Feb 6, 2023 | 74.45 | 0.03 | 0.04% | 74.42 | 75.09 | 73.98 |
| Feb 3, 2023 | 74.35 | 1.78 | 2.45% | 72.57 | 74.38 | 72.34 |
| Feb 2, 2023 | 72.66 | 2.68 | 3.83% | 69.98 | 72.80 | 69.32 |
| Feb 1, 2023 | 71.10 | -1.20 | -1.66% | 72.30 | 72.76 | 69.93 |
| Jan 31, 2023 | 72.58 | 0.95 | 1.33% | 71.63 | 72.58 | 71.56 |
| Jan 30, 2023 | 71.96 | -0.32 | -0.44% | 72.28 | 72.82 | 71.77 |
| Jan 27, 2023 | 72.37 | -0.20 | -0.28% | 72.57 | 73.37 | 72.19 |
| Jan 26, 2023 | 72.90 | 0.30 | 0.41% | 72.60 | 73.11 | 71.83 |
| Jan 25, 2023 | 73.07 | 0.68 | 0.94% | 72.39 | 73.16 | 71.79 |
| Jan 24, 2023 | 72.28 | -0.48 | -0.66% | 72.76 | 73.38 | 71.93 |
| Jan 23, 2023 | 73.15 | -0.78 | -1.06% | 73.93 | 74.11 | 72.73 |
| Jan 20, 2023 | 74.07 | 0.30 | 0.41% | 73.77 | 74.07 | 73.22 |
| Jan 19, 2023 | 73.67 | 2.24 | 3.14% | 71.43 | 73.79 | 71.43 |
| Jan 18, 2023 | 72.07 | 0.11 | 0.15% | 71.96 | 72.59 | 71.07 |
| Jan 17, 2023 | 72.23 | -0.67 | -0.92% | 72.90 | 73.38 | 71.91 |
| Jan 13, 2023 | 72.42 | 0.92 | 1.29% | 71.50 | 72.44 | 71.23 |
| Jan 12, 2023 | 71.53 | 0.08 | 0.11% | 71.45 | 71.86 | 70.93 |
| Jan 11, 2023 | 71.85 | 0.38 | 0.53% | 71.47 | 71.90 | 70.79 |
| Jan 10, 2023 | 71.58 | 0.44 | 0.62% | 71.14 | 71.62 | 70.57 |
Bristol-Myers Squibb Co Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Metinis
- Kas ketvirtį
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Visos pajamos | 19427 | 20776 | 22561 | 26145 | 42518 | 46385 |
| Pajamos | 19427 | 20776 | 22561 | 26145 | 42518 | 46385 |
| Bendros pajamos, iš viso | 4925 | 5917 | 6436 | 7804 | 11133 | 9601 |
| Pajamos | 14502 | 14859 | 16125 | 18341 | 31385 | 36784 |
| Pajamų sąnaudos, iš viso | 13480 | 15532 | 16175 | 19758 | 49365 | 37770 |
| Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 4911 | 4687 | 4550 | 4870 | 7733 | 7688 |
| Tyrimai ir plėtra | 4927 | 4823 | 5052 | 5845 | 9519 | 9532 |
| Depreciation / Amortization | 21 | 3 | 41 | 1206 | 9688 | 10023 |
| Neįprastos išlaidos (pajamos) | -585 | 1453 | 1449 | 1393 | 12819 | 2659 |
| Other Operating Expenses, Total | -719 | -1351 | -1353 | -1360 | -1527 | -1733 |
| Veiklos pajamos | 5947 | 5244 | 6386 | 6387 | -6847 | 8615 |
| Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | 15 | 33 | -380 | -69 | -71 | -550 |
| Kita, pajamos | -47 | -146 | -38 | -1343 | 47 | 33 |
| Grynosios pajamos prieš mokesčius | 5915 | 5131 | 5968 | 4975 | -6871 | 8098 |
| Grynosios pajamos po mokesčių | 4507 | 3871 | 5003 | 3460 | -8995 | 7014 |
| Mažumos palūkanos | -50 | 32 | -27 | -21 | -20 | -20 |
| Grynosios pajamos prieš papildomas. Prekės | 4457 | 3903 | 4976 | 3439 | -9015 | 6994 |
| Grynosios pajamos | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 |
| Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | 4457 | 3903 | 4976 | 3439 | -9015 | 6994 |
| Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 |
| Skiedžiamas grynasis pelnas | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 |
| Skiedžiamas svertinis vidutinis akcijų skaičius | 1680 | 1652 | 1637 | 1712 | 2258 | 2245 |
| Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | 2.65298 | 2.36259 | 3.03971 | 2.00876 | -3.99247 | 3.11537 |
| Dividends per Share - Common Stock Primary Issue | 1.52 | 1.56 | 1.6 | 1.64 | 1.8 | 1.96 |
| Skiedžiamas normalizuotas pelnas, gautas iš pelno | 2.38949 | 3.03729 | 3.78174 | 2.58034 | -0.19982 | 3.81069 |
| Iš viso nepaprastųjų prekių | -2896 | -56 | 0 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Visos pajamos | 11073 | 11703 | 11624 | 11985 | 11648 |
| Pajamos | 11073 | 11703 | 11624 | 11985 | 11648 |
| Bendros pajamos, iš viso | 2503 | 2451 | 2291 | 2356 | 2471 |
| Pajamos | 8570 | 9252 | 9333 | 9629 | 9177 |
| Pajamų sąnaudos, iš viso | 8812 | 9988 | 9628 | 9342 | 9095 |
| Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 1667 | 1882 | 1787 | 2352 | 1829 |
| Tyrimai ir plėtra | 2225 | 2261 | 2440 | 2607 | 2220 |
| Depreciation / Amortization | 2513 | 2547 | 2546 | 2417 | 2417 |
| Neįprastos išlaidos (pajamos) | 271 | 1252 | 989 | 146 | 635 |
| Other Operating Expenses, Total | -367 | -405 | -425 | -536 | -477 |
| Veiklos pajamos | 2261 | 1715 | 1996 | 2643 | 2553 |
| Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | 257 | -170 | 149 | -786 | -960 |
| Kita, pajamos | 12 | 8 | 12 | 1 | 94 |
| Grynosios pajamos prieš mokesčius | 2530 | 1553 | 2157 | 1858 | 1687 |
| Grynosios pajamos po mokesčių | 2029 | 1061 | 1552 | 2372 | 1283 |
| Mažumos palūkanos | -8 | -6 | -6 | 0 | -5 |
| Grynosios pajamos prieš papildomas. Prekės | 2021 | 1055 | 1546 | 2372 | 1278 |
| Grynosios pajamos | 2021 | 1055 | 1546 | 2372 | 1278 |
| Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | 2021 | 1055 | 1546 | 2372 | 1278 |
| Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | 2021 | 1055 | 1546 | 2372 | 1278 |
| Skiedžiamas grynasis pelnas | 2021 | 1055 | 1546 | 2372 | 1278 |
| Skiedžiamas svertinis vidutinis akcijų skaičius | 2265 | 2252 | 2243 | 2221 | 2164 |
| Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | 0.89227 | 0.46847 | 0.68926 | 1.06799 | 0.59057 |
| Dividends per Share - Common Stock Primary Issue | 0.49 | 0.49 | 0.49 | 0.49 | 0.54 |
| Skiedžiamas normalizuotas pelnas, gautas iš pelno | 0.89007 | 0.85213 | 1.0486 | 1.02071 | 0.81817 |
- Metinis
- Kas ketvirtį
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Trumpalaikis turtas iš viso | 13704 | 14854 | 17160 | 29354 | 30192 | 33262 |
| Pinigai ir trumpalaikės investicijos | 6350 | 6812 | 8884 | 15393 | 15831 | 16966 |
| Pinigai ir ekvivalentai | 4237 | 5421 | 6911 | 12346 | 14546 | 13979 |
| Trumpalaikės investicijos | 2113 | 1391 | 1973 | 3047 | 1285 | 2987 |
| Gautinos sumos, iš viso, grynąja verte | 4916 | 5609 | 5747 | 7685 | 8501 | 9369 |
| Accounts Receivable - Trade, Net | 3774 | 4347 | 4636 | 6476 | 7219 | 7979 |
| Total Inventory | 1241 | 1166 | 1195 | 4293 | 2074 | 2095 |
| Prepaid Expenses | 627 | 691 | 218 | 754 | 1799 | 2786 |
| Other Current Assets, Total | 570 | 576 | 1116 | 1229 | 1987 | 2046 |
| Total Assets | 33707 | 33551 | 34986 | 129944 | 118481 | 109314 |
| Property/Plant/Equipment, Total - Net | 4980 | 5001 | 5027 | 6956 | 6745 | 6968 |
| Property/Plant/Equipment, Total - Gross | 9173 | 8987 | 8845 | 10911 | 10330 | 11001 |
| Accumulated Depreciation, Total | -4193 | -3986 | -3818 | -3955 | -3585 | -4033 |
| Goodwill, Net | 6875 | 6863 | 6538 | 22488 | 20547 | 20502 |
| Intangibles, Net | 1385 | 1210 | 1091 | 63969 | 53243 | 42527 |
| Long Term Investments | 2719 | 2480 | 1775 | 4601 | 4509 | 2713 |
| Other Long Term Assets, Total | 4044 | 3143 | 3395 | 2576 | 3245 | 3342 |
| Total Current Liabilities | 8841 | 9563 | 10654 | 18304 | 19080 | 21868 |
| Accounts Payable | 1664 | 2248 | 1892 | 2445 | 2713 | 2949 |
| Accrued Expenses | 4587 | 5313 | 5687 | 8100 | 9582 | 10104 |
| Notes Payable/Short Term Debt | 243 | 987 | 454 | 583 | 340 | 184 |
| Current Port. of LT Debt/Capital Leases | 749 | 0 | 1249 | 2763 | 2000 | 4764 |
| Other Current Liabilities, Total | 1598 | 1015 | 1372 | 4413 | 4445 | 3867 |
| Total Liabilities | 17530 | 21810 | 20955 | 78346 | 80659 | 73368 |
| Total Long Term Debt | 5716 | 6975 | 5646 | 43387 | 48336 | 39605 |
| Long Term Debt | 5716 | 6975 | 5646 | 43387 | 48336 | 39605 |
| Minority Interest | 170 | 106 | 96 | 100 | 60 | 60 |
| Other Liabilities, Total | 2803 | 5166 | 4559 | 10101 | 7776 | 7334 |
| Total Equity | 16177 | 11741 | 14031 | 51598 | 37822 | 35946 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 221 | 221 | 221 | 292 | 292 | 292 |
| Additional Paid-In Capital | 1725 | 1898 | 2081 | 43709 | 44325 | 44361 |
| Retained Earnings (Accumulated Deficit) | 33513 | 31160 | 34065 | 34474 | 21281 | 23820 |
| Treasury Stock - Common | -16779 | -19249 | -19574 | -25357 | -26237 | -31259 |
| Unrealized Gain (Loss) | -7 | 32 | -30 | 6 | 11 | 2 |
| Other Equity, Total | -2496 | -2321 | -2732 | -1526 | -1850 | -1270 |
| Total Liabilities & Shareholders’ Equity | 33707 | 33551 | 34986 | 129944 | 118481 | 109314 |
| Total Common Shares Outstanding | 1664 | 1625 | 1624 | 2228 | 2221 | 2153 |
| Total Preferred Shares Outstanding | 0.00413 | 0.00407 | ||||
| Deferred Income Tax | 6454 | 5407 | 4501 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Trumpalaikis turtas iš viso | 27111 | 29161 | 31443 | 33262 | 30121 |
| Pinigai ir trumpalaikės investicijos | 12930 | 14016 | 15823 | 16966 | 14968 |
| Pinigai ir ekvivalentai | 10982 | 11024 | 13540 | 13979 | 12369 |
| Trumpalaikės investicijos | 1948 | 2992 | 2283 | 2987 | 2599 |
| Gautinos sumos, iš viso, grynąja verte | 8660 | 11275 | 11738 | 9369 | 8511 |
| Accounts Receivable - Trade, Net | 7187 | 7713 | 7878 | 7979 | 7156 |
| Total Inventory | 1953 | 2137 | 2163 | 2095 | 2104 |
| Other Current Assets, Total | 3568 | 1733 | 1719 | 2046 | 4538 |
| Total Assets | 112435 | 110797 | 110893 | 109314 | 103034 |
| Property/Plant/Equipment, Total - Net | 6613 | 6801 | 6835 | 6968 | 6941 |
| Property/Plant/Equipment, Total - Gross | 10243 | 10639 | 10805 | 11001 | 11109 |
| Accumulated Depreciation, Total | -3630 | -3838 | -3970 | -4033 | -4168 |
| Goodwill, Net | 20524 | 20529 | 20519 | 20502 | 20500 |
| Intangibles, Net | 50819 | 48065 | 44930 | 42527 | 40103 |
| Long Term Investments | 4636 | 3765 | 4784 | 2713 | 2185 |
| Other Long Term Assets, Total | 2732 | 2476 | 2382 | 3342 | 3184 |
| Total Current Liabilities | 17330 | 18991 | 21460 | 21868 | 22821 |
| Accounts Payable | 2972 | 3609 | 2695 | 2949 | 2944 |
| Accrued Expenses | 8491 | 8962 | 9971 | 10104 | 8319 |
| Notes Payable/Short Term Debt | 277 | 158 | 296 | 184 | 225 |
| Current Port. of LT Debt/Capital Leases | 1500 | 2497 | 4769 | 4764 | 7297 |
| Other Current Liabilities, Total | 4090 | 3765 | 3729 | 3867 | 4036 |
| Total Liabilities | 74830 | 73989 | 73680 | 73368 | 71454 |
| Total Long Term Debt | 44505 | 42503 | 39677 | 39605 | 37450 |
| Long Term Debt | 44505 | 42503 | 39677 | 39605 | 37450 |
| Deferred Income Tax | 5235 | 4931 | 4956 | 4501 | 3809 |
| Minority Interest | 68 | 66 | 71 | 60 | 65 |
| Other Liabilities, Total | 7692 | 7498 | 7516 | 7334 | 7309 |
| Total Equity | 37605 | 36808 | 37213 | 35946 | 31580 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 292 | 292 | 292 | 292 | 292 |
| Additional Paid-In Capital | 43852 | 44064 | 44292 | 44361 | 43756 |
| Retained Earnings (Accumulated Deficit) | 22204 | 22168 | 22625 | 23820 | 23948 |
| Treasury Stock - Common | -27199 | -28198 | -28572 | -31259 | -35187 |
| Unrealized Gain (Loss) | 9 | 7 | 4 | 2 | 1 |
| Other Equity, Total | -1553 | -1525 | -1428 | -1270 | -1230 |
| Total Liabilities & Shareholders’ Equity | 112435 | 110797 | 110893 | 109314 | 103034 |
| Total Common Shares Outstanding | 2232.84 | 2222.11 | 2219.65 | 2153 | 2129.06 |
| Prepaid Expenses | 2786 |
- Metinis
- Kas ketvirtį
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Grynosios pajamos / pradinė eilutė | 4507 | 975 | 4947 | 3460 | -8995 | 7014 |
| Pagrindinės veiklos pinigai | 3058 | 5275 | 5940 | 8067 | 14052 | 16207 |
| Pagrindinės veiklos pinigai | 382 | 789 | 637 | 1746 | 10380 | 10686 |
| Deferred Taxes | -204 | 1010 | 86 | -924 | 983 | -1393 |
| Nepiniginės prekės | -475 | 913 | 94 | 720 | 10701 | 1153 |
| Cash Taxes Paid | 2000 | 546 | 747 | 1503 | 3400 | 3500 |
| Sumokėtos palūkanos grynaisiais pinigais | 191 | 215 | 212 | 414 | 1600 | 1500 |
| Apyvartinio kapitalo pokyčiai | -1152 | 1588 | 176 | 3065 | 983 | -1253 |
| Investicinės veiklos pinigai | 1480 | -66 | -874 | -9770 | -10859 | -538 |
| Kapitalo išlaidos | -1215 | -1055 | -951 | -836 | -753 | -973 |
| Kiti investiciniai pinigų srautų iš prekių, iš viso | 2695 | 989 | 77 | -8934 | -10106 | 435 |
| Finansinės veiklos pinigai | -2653 | -4077 | -3535 | 7621 | -1151 | -16224 |
| Finansavimo pinigų srautų prekės | 15 | -22 | -54 | -53 | 542 | 641 |
| Total Cash Dividends Paid | -2547 | -2577 | -2613 | -2679 | -4075 | -4396 |
| Akcijų išleidimas (išpirkimas), grynasis | -231 | -2469 | -320 | -7300 | -1546 | -6287 |
| Skolos išleidimas (padengimas), grynasis | 110 | 991 | -548 | 17653 | 3928 | -6182 |
| Užsienio valiutos keitimo įtaka | -33 | 52 | -41 | -9 | 111 | -102 |
| Grynasis pinigų pokytis | 1852 | 1184 | 1490 | 5909 | 2153 | -657 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 2029 | 3090 | 4642 | 7014 | 1283 |
| Cash From Operating Activities | 3824 | 6884 | 12150 | 16207 | 3812 |
| Cash From Operating Activities | 2668 | 5380 | 8107 | 10686 | 2584 |
| Deferred Taxes | 68 | -95 | -127 | -1393 | -687 |
| Non-Cash Items | -507 | 356 | 725 | 1153 | 994 |
| Changes in Working Capital | -434 | -1847 | -1197 | -1253 | -362 |
| Cash From Investing Activities | -143 | 37 | -939 | -538 | 95 |
| Capital Expenditures | -173 | -383 | -653 | -973 | -253 |
| Other Investing Cash Flow Items, Total | 30 | 420 | -286 | 435 | 348 |
| Cash From Financing Activities | -7295 | -10477 | -12257 | -16224 | -5653 |
| Financing Cash Flow Items | 172 | 448 | 644 | 641 | 333 |
| Total Cash Dividends Paid | -1108 | -2207 | -3297 | -4396 | -1185 |
| Issuance (Retirement) of Stock, Net | -1775 | -3011 | -3536 | -6287 | -5000 |
| Issuance (Retirement) of Debt, Net | -4584 | -5707 | -6068 | -6182 | 199 |
| Foreign Exchange Effects | -38 | -20 | -48 | -102 | 9 |
| Net Change in Cash | -3652 | -3576 | -1094 | -657 | -1737 |
| Investuotojo pavadinimas | Investuotojo tipas | Apyvartoje esantis procentas | Turimos akcijos | Turimų akcijų pokytis | Turėjimo data | Apyvartos vertinimas |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.3545 | 198890804 | 3066015 | 2022-09-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.2989 | 112662905 | 2240471 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.3424 | 92325898 | -602471 | 2022-09-30 | LOW |
| JP Morgan Asset Management | Investment Advisor | 3.0052 | 63894939 | 526421 | 2022-09-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.9555 | 62838772 | -1753198 | 2022-09-30 | LOW |
| Capital International Investors | Investment Advisor | 2.4644 | 52396432 | 14298520 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8412 | 39147135 | 1131303 | 2022-09-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.5702 | 33385956 | -2374239 | 2022-09-30 | LOW |
| BofA Global Research (US) | Research Firm | 1.0777 | 22914303 | 1075724 | 2022-09-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0666 | 22677818 | -372517 | 2021-12-31 | LOW |
| Managed Account Advisors LLC | Investment Advisor | 1.0476 | 22273448 | -2068389 | 2022-09-30 | LOW |
| PRIMECAP Management Company | Investment Advisor | 1.0412 | 22137675 | -74030 | 2022-09-30 | LOW |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.9424 | 20037642 | -147066 | 2022-09-30 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 0.789 | 16775562 | -1577777 | 2022-09-30 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7761 | 16501572 | -551586 | 2022-09-30 | LOW |
| Nuveen LLC | Pension Fund | 0.7673 | 16313175 | 698391 | 2022-09-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7056 | 15001848 | -146955 | 2022-09-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.6895 | 14659982 | 155845 | 2022-09-30 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.6759 | 14370082 | -23245 | 2022-09-30 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.6643 | 14124064 | -3100460 | 2022-09-30 | LOW |
Kodėl Capital.com? Mūsų skaičiai kalba už save.
Capital.com Group +500000+
Prekeiviai
93000+
Aktyvūs klientai kas mėnesį
$57000000+
Mėnesio investicijų apimtis
$31000000+
Išbandykite dabar Atsiimama kas mėnesį
Prekybos skaičiuoklė
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Sandorio komisiniai mokesčiai
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Svertas
20:1
- 20
- 100
- 500
- 1000
- 10000
Investavimas
Sandorio dydis (finansinis svertas x investicija):
Atidarymas
Uždarymas
Trumpoji Ilgoji
Bristol-Myers Squibb Company profile
Apie Bristol-Myers Squibb Co
"Bristol-Myers Squibb Company" yra biofarmacijos bendrovė. Bendrovė užsiima biofarmacinių produktų atradimu, kūrimu, licencijavimu, gamyba, rinkodara, platinimu ir pardavimu. Bendrovė siūlo produktus įvairioms terapinėms klasėms, įskaitant onkologiją, imunologiją, širdies ir kraujagyslių bei fibrozę. Bendrovės farmacinius produktus sudaro chemiškai susintetinti arba mažų molekulių vaistai ir biologinių procesų metu pagaminti produktai, vadinami biologiniais vaistais. Mažų molekulių vaistai vartojami per burną kaip tabletės ar tabletės. Biologiniai vaistai pacientams skiriami injekcijomis arba infuzijomis. Bendrovės produktai yra "Revlimid", "Eliquis", "Opdivo", "Orencia", "Pomalyst/Imnovid", "Sprycel", "Yervoy", "Abraxane", "Empliciti", "Reblozyl", "Inrebic", "Onureg", "Zeposia", "Vidaza", "Baraclude" ir "Breyanzi". Produktai parduodami didmenininkams, platintojams, vaistinėms, mažmenininkams, ligoninėms, klinikoms ir valstybinėms įstaigoms.
| Industry: | Pharmaceuticals (NEC) |
430 E. 29Th Street
14 Floor
NEW YORK
NEW YORK 10016
US
Pajamų ataskaita
- Annual
- Quarterly
Žmonės taip pat žiūri
Vis dar ieškote brokerio kuriuo galėtumėte pasitikėti?
Prisijunkite prie 500 000+ prekeivių visame pasaulyje, kurie pasirinko prekybą su Capital.com